H. pylori persistence, PAQ subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days may leads to lower H. pylori persistence, PAQ subgroup compared with 7 days (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to higher patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, regardless of regimen and dose · patients with Helicobacter pylori infection
PPI triple therapy for 10 days probably leads to lower H. pylori persistence, regardless of regimen and dose compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PCA subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 10 days probably leads to lower H. pylori persistence, PCA subgroup compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PCN subgroup · patients with Helicobacter pylori infection
It is very uncertain whether PPI triple therapy for 10 days changes H. pylori persistence, PCN subgroup compared with 7 days (very low certainty).
1 finding from 1 review
Clinical relapse · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether any‐treatment‐dose vitamin D (greater than 400 IU/day) changes withdrawals due to adverse events compared with supplemental‐dose vitamin D (less than 400 IU/day) (very low certainty).
1 finding from 1 review
Clinical response · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with inflammatory bowel disease
High‐treatment‐dose vitamin D (greater than 1000 IU/day) showed no clear difference in clinical relapse at end of study (52 weeks) compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (low certainty).
1 finding from 1 review
Quality of life · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
1 finding from 1 review
Intervention not reported
Incidence of AAD: Probiotic dose (≥5 billion CFUs of probiotics/day) · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
The intervention probably leads to lower incidence of AAD: Probiotic dose (≥5 billion CFUs of probiotics/day) (moderate certainty).
1 finding from 1 review
Intervention not reported
Duration of diarrhea (days) · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
1 finding from 1 review
Not symptom‐free or no symptom improvement · patients with functional dyspepsia
It is very uncertain whether other prokinetics changes not symptom‐free or no symptoms improvement (itopride 50 three times… compared with domperidone 10mg three times a day (very low certainty).
1 finding from 1 review
Mean change in baseline CDAI (Random effects model) · patients with Induction of remission or response in Crohn's disease
1 finding from 1 review
Mean change in baseline CDAI (Fixed effects model) · patients with Induction of remission or response in Crohn's disease
1 finding from 1 review
Decrease in CDAI >=50, HBI >=2 or improvement/remission (as defined by Tvede et al) · patients with Induction of remission or response in Crohn's disease
Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in decrease in CDAI >=50, HBI >=2 or improvement/remission (as defined… compared with placebo (low certainty).
1 finding from 1 review
Induction of remission (CDAI <=150 + decrease of >=50 or as defined by Tvede et al) · patients with Induction of remission or response in Crohn's disease
Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in induction of remission (CDAI <=150 + decrease of >=50 or as defined… compared with placebo (low certainty).
1 finding from 1 review